N-[4-(3-methylphenyl)aminopyridin-3-yl]sulfonylmethanamide

N-[4-(3-methylphenyl)aminopyridin-3-yl]sulfonylmethanamide Brand names, N-[4-(3-methylphenyl)aminopyridin-3-yl]sulfonylmethanamide Analogs

N-[4-(3-methylphenyl)aminopyridin-3-yl]sulfonylmethanamide Brand Names Mixture

No information avaliable

N-[4-(3-methylphenyl)aminopyridin-3-yl]sulfonylmethanamide Chemical_Formula

C₁₆H₂₀N₄O₃S

N-[4-(3-methylphenyl)aminopyridin-3-yl]sulfonylmethanamide RX_link

http://www.rxlist.com/cgi/generic/demadex.htm

N-[4-(3-methylphenyl)aminopyridin-3-yl]sulfonylmethanamide fda sheet

N-[4-(3-methylphenyl)aminopyridin-3-yl]sulfonylmethanamide msds (material safety sheet)

N-[4-(3-methylphenyl)aminopyridin-3-yl]sulfonylmethanamide MSDS

N-[4-(3-methylphenyl)aminopyridin-3-yl]sulfonylmethanamide Synthesis Reference

No information avaliable

N-[4-(3-methylphenyl)aminopyridin-3-yl]sulfonylmethanamide Molecular Weight

348.421 g/mol

N-[4-(3-methylphenyl)aminopyridin-3-yl]sulfonylmethanamide Melting Point

163-164 ^oC (decomposition)

N-[4-(3-methylphenyl)aminopyridin-3-yl]sulfonylmethanamide H₂O Solubility

Soluble

N-[4-(3-methylphenyl)aminopyridin-3-yl]sulfonylmethanamide State

Solid

N-[4-(3-methylphenyl)aminopyridin-3-yl]sulfonylmethanamide LogP

2.404

N-[4-(3-methylphenyl)aminopyridin-3-yl]sulfonylmethanamide Dosage Forms

Liquid; Tablet

N-[4-(3-methylphenyl)aminopyridin-3-yl]sulfonylmethanamide Indication

For the treatment of hypertension, edema induced by congestive heart failure or renal disease, and ascites associated with hepatic disease.

N-[4-(3-methylphenyl)aminopyridin-3-yl]sulfonylmethanamide Pharmacology

Torasemide, a monosulfonamyl loop diuretic, differs form other thiazide diuretics in that a double ring system is incorporated into its structure. Torasemide is used alone or with atenolol in the management of hypertension and edema. Micropuncture studies in animals have shown that torsemide acts from within the lumen of the thick ascending portion of the loop of Henle, where it inhibits the Na⁺/K⁺/2Cl^--carrier system.

N-[4-(3-methylphenyl)aminopyridin-3-yl]sulfonylmethanamide Absorption

Bioavailability is approximately 80%. Serum concentration peaks after approximately 1 hour.

N-[4-(3-methylphenyl)aminopyridin-3-yl]sulfonylmethanamide side effects and Toxicity

LD₅₀ = 5 g/kg (rat, oral), 500 mg/kg (rat, intravenous). Side effects include dizziness, headache, nausea and vomiting.

N-[4-(3-methylphenyl)aminopyridin-3-yl]sulfonylmethanamide Patient Information